Abstract

While the importance of the iron-load of lipocalin-2 (Lcn-2) in promoting tumor progression is widely appreciated, underlying molecular mechanisms largely remain elusive. Considering its role as an iron-transporter, we aimed at clarifying iron-loaded, holo-Lcn-2 (hLcn-2)-dependent signaling pathways in affecting renal cancer cell viability. Applying RNA sequencing analysis in renal CAKI1 tumor cells to explore highly upregulated molecular signatures in response to hLcn-2, we identified a cluster of genes (SLC7A11, GCLM, GLS), which are implicated in regulating ferroptosis. Indeed, hLcn-2-stimulated cells are protected from erastin-induced ferroptosis. We also noticed a rapid increase in reactive oxygen species (ROS) with subsequent activation of the antioxidant Nrf2 pathway. However, knocking down Nrf2 by siRNA was not sufficient to induce erastin-dependent ferroptotic cell death in hLcn-2-stimulated tumor cells. In contrast, preventing oxidative stress through N-acetyl-l-cysteine (NAC) supplementation was still able to induce erastin-dependent ferroptotic cell death in hLcn-2-stimulated tumor cells. Besides an oxidative stress response, we noticed activation of the integrated stress response (ISR), shown by enhanced phosphorylation of eIF-2α and induction of ATF4 after hLcn-2 addition. ATF4 knockdown as well as inhibition of the ISR sensitized hLcn-2-treated renal tumor cells to ferroptosis, thus linking the ISR to pro-tumor characteristics of hLcn-2. Our study provides mechanistic details to better understand tumor pro-survival pathways initiated by iron-loaded Lcn-2.

Highlights

  • IntroductionOne of the most recurrent urologic tumors is renal cell carcinoma (RCC)

  • We identified SLC7A11, GCLM, and GLS, which cluster within the GO-terms, referring to glutathione biosynthesis and inhibiting ferroptotic cell death (Figure 1C)

  • We provide evidence that a coordinated response of reactive oxygen species (ROS) besides induction of the integrated stress response (ISR)/p-eIF2α/activating transcription factor 4 (ATF4)-axis fosters protection against erastin-induced ferroptosis

Read more

Summary

Introduction

One of the most recurrent urologic tumors is renal cell carcinoma (RCC). Due to its clinically silent development and progression, RCC represents a major, yet underestimated health problem, since the detection of the majority of RCC cases is by incidental radiologic discovery [1]. Resistance of RCC against chemo- and radiation-therapy further restricts therapeutic medical options [2]. No reliable diagnostic approach for early RCC detection and no effective method for recurrence surveillance or therapy response are available. It appears pivotal to identify suitable diagnostic and prognostic biomarkers, in order to enable detection of premetastatic tumors and to install efficient therapy approaches such as partial rather than radical nephrectomy.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call